Novartis | NOVN - Operating Profit


Novartis reported $4.75B in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Alcon AG USD 297M 16M Mar/2026
Almirall EUR 71.55M 41.32M Jun/2026
Amgen USD 4.61B 777M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Autolus Therapeutics Ltd USD -59.51M 12.95M Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
Biogen USD -243.8M 758.1M Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Fresenius EUR 719M 118M Jun/2026
Fresenius Medical Care EUR 268M 395M Mar/2026
Genmab DKK 407M 182M Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
GRIFOLS EUR 329M 80M Jun/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
J&J USD 7.48B 860M Jun/2026
Lakefront Biotherapeutics EUR -63.7M 844.26M Mar/2026
Lonza CHF 673M 243M Jun/2025
Merck EUR 1.05B 572M Mar/2026
Merck USD 840M 2.72B Jun/2026
Novartis USD 4.75B 515M Jun/2026
Novartis USD 4.24B 171M Mar/2026
Novo Nordisk DKK 33.76B 25.86B Jun/2026
Orion EUR 176.6M 61.8M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Philips EUR 610M 308M Jun/2026
Recordati EUR 203.76M 27.35M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 2.38B 449M Jun/2026
UCB EUR 1.29B 571M Dec/2025